MINI FUTURE LONG - VETOQUINOL | Market Closed - Börse Stuttgart 10:24:58 2024-06-05 EDT | ||
| 3.08 EUR | -9.14% |
|
| Current month | +3.35% | ||
| 1 month | +29.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
VETOQUINOL SA
Latest news about VETOQUINOL SA
| Date | Price | Change |
|---|---|---|
| 24-06-05 | 3.08 | -9.14% |
| 24-06-04 | 3.39 | -1.45% |
| 24-06-03 | 3.44 | +4.88% |
| 24-05-31 | 3.28 | +3.80% |
| 24-05-30 | 3.16 | -3.36% |
Delayed Quote Börse Stuttgart
Last update June 05, 2024 at 10:24 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VETOQUINOL SA |
| Issuer | Morgan Stanley |
| WKN | MB8ZC0 |
| ISIN | DE000MB8ZC07 |
| Date issued | 2023-07-19 |
| Strike | 68.86 € |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.14 € |
|---|---|
| Lowest since issue | 1.12 € |
Company Profile
Vetoquinol SA specializes in the research, development, production and marketing of veterinary drugs and products for pets (67.7% of net sales; dogs, cats, etc.) and livestock (32.3%; cattle, pigs, poultry, etc.). The group's activity is organized around 4 product families:
- antibiotics;
- anti-inflammatories;
- cardiology and nephrology treatments;
- other: anti-parasitics, vaccines, and nutritional products.
At the end of 2022, the group had 5 production sites throughout the world.
Net sales are distributed geographically as follows: Europe (46.7%), the Americas (36%) and Asia/Pacific (17.3%).
Sector
-
Consensus: Vetoquinol SA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
99.4
EUR
Average target price
105.8
EUR
Spread / Average Target
+6.47%
- Stock Market
- Certificates
- Certificat
